AU2020216498B2 - Bicyclic pyridine compositions and methods of using the same for cancer therapy - Google Patents

Bicyclic pyridine compositions and methods of using the same for cancer therapy

Info

Publication number
AU2020216498B2
AU2020216498B2 AU2020216498A AU2020216498A AU2020216498B2 AU 2020216498 B2 AU2020216498 B2 AU 2020216498B2 AU 2020216498 A AU2020216498 A AU 2020216498A AU 2020216498 A AU2020216498 A AU 2020216498A AU 2020216498 B2 AU2020216498 B2 AU 2020216498B2
Authority
AU
Australia
Prior art keywords
cancer
compound
pct
auc
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020216498A
Other languages
English (en)
Other versions
AU2020216498A1 (en
Inventor
Mengqian CHEN
Jing Li
Jiaxin LIANG
Campbell Mcinnes
Igor B. Roninson
Li Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Carolina
Senex Biotechnology Inc
Original Assignee
University of South Carolina
Senex Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Carolina, Senex Biotechnology Inc filed Critical University of South Carolina
Publication of AU2020216498A1 publication Critical patent/AU2020216498A1/en
Application granted granted Critical
Publication of AU2020216498B2 publication Critical patent/AU2020216498B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2020216498A 2019-02-01 2020-02-03 Bicyclic pyridine compositions and methods of using the same for cancer therapy Active AU2020216498B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962800239P 2019-02-01 2019-02-01
US62/800,239 2019-02-01
PCT/US2020/016394 WO2020160537A1 (en) 2019-02-01 2020-02-03 Bicyclic pyridine compositions and methods of using the same for cancer therapy

Publications (2)

Publication Number Publication Date
AU2020216498A1 AU2020216498A1 (en) 2021-09-23
AU2020216498B2 true AU2020216498B2 (en) 2025-08-28

Family

ID=71842384

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020216498A Active AU2020216498B2 (en) 2019-02-01 2020-02-03 Bicyclic pyridine compositions and methods of using the same for cancer therapy

Country Status (8)

Country Link
US (1) US11572369B2 (enExample)
EP (1) EP3917523B1 (enExample)
JP (1) JP7628252B2 (enExample)
CN (1) CN113677341B (enExample)
AU (1) AU2020216498B2 (enExample)
CA (1) CA3128377A1 (enExample)
ES (1) ES2991429T3 (enExample)
WO (1) WO2020160537A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024193640A1 (zh) * 2023-03-22 2024-09-26 上海齐鲁制药研究中心有限公司 Cdk抑制剂

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1764367A1 (en) * 2004-04-12 2007-03-21 Sankyo Company, Limited Thienopyridine derivatives
JP2008260693A (ja) * 2007-04-10 2008-10-30 Daiichi Sankyo Co Ltd チエノピリジン−２−カルボキサミド誘導体を含有する医薬組成物
WO2014071143A1 (en) * 2012-11-01 2014-05-08 University Of South Carolina Method for treating prostate cancer
WO2015100420A1 (en) * 2013-12-24 2015-07-02 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
US20160000787A1 (en) * 2013-02-26 2016-01-07 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
WO2016009076A1 (en) * 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
WO2017076968A1 (en) * 2015-11-03 2017-05-11 Lu License Ab Compounds for treatment of hypoproliferative disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271723A (en) 1976-11-19 1981-06-09 Caterpillar Tractor Co. Power train with an auxiliary creeper drive system
GB9402029D0 (en) 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
DE60325051D1 (de) 2002-06-06 2009-01-15 Boehringer Ingelheim Pharma SUBSTITUIERTE 3-AMINO-THIENO(2,3-b)PYRIDINE-2-AMIDE UND HERSTELLUNGSVERFAHREN SOWIE DEREN VERWENDUNG
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US20070021927A1 (en) 2005-07-21 2007-01-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Selective resonance of chemical structures
US20070207201A1 (en) 2006-03-06 2007-09-06 Wyeth Liquid and Semi-Solid Pharmaceutical Formulations and Processes
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
EP2489354A1 (en) 2011-02-18 2012-08-22 Vironova AB Pharmaceutical formulation of B220 for topical treatment of herpes
EA027531B1 (ru) 2011-09-13 2017-08-31 Игорь Ронинсон ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-κB
KR20150023223A (ko) 2012-02-02 2015-03-05 세넥스 바이오테크놀러지 인코포레이티드 Ｃｄｋ8/ｃｄｋ19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도
WO2014087240A2 (en) * 2012-12-04 2014-06-12 Dalhousie University Compositions, methods and kits for preventing, reducing, and eliminating cancer metastasis
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
WO2014164543A1 (en) * 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2014194245A2 (en) 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof
US9937153B2 (en) 2013-08-30 2018-04-10 Merck Sharp & Dohme Ltd. Oral pharmaceutical formulation of omarigliptin
US9566280B2 (en) * 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
NZ722345A (en) * 2014-02-14 2018-02-23 Inception 2 Inc Pyrazolone compounds and uses thereof
WO2016018511A2 (en) 2014-06-10 2016-02-04 University Of South Carolina Methods and compositions for treatment of her-positive cancers
WO2016041618A1 (en) * 2014-09-15 2016-03-24 Merck Patent Gmbh Substituted indazoles and related heterocycles
US20210322651A1 (en) 2014-12-18 2021-10-21 Senex Biotechnology, Inc. Suppression of neointimal formation following vascular surgeru using cdk8 inhibitors
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
WO2020237014A1 (en) * 2019-05-21 2020-11-26 University Of South Carolina 3-amino-4-(4-(4 (dimethylcarbamoyl) phenyl)-1,4-diazepan-1-yl) thieno [2,3-b] pyridine-2-carboxamide for use in cancer therapy and formulations comprising the same

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1764367A1 (en) * 2004-04-12 2007-03-21 Sankyo Company, Limited Thienopyridine derivatives
JP2008260693A (ja) * 2007-04-10 2008-10-30 Daiichi Sankyo Co Ltd チエノピリジン−２−カルボキサミド誘導体を含有する医薬組成物
WO2014071143A1 (en) * 2012-11-01 2014-05-08 University Of South Carolina Method for treating prostate cancer
US20160000787A1 (en) * 2013-02-26 2016-01-07 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
WO2015100420A1 (en) * 2013-12-24 2015-07-02 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2016009076A1 (en) * 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
WO2017076968A1 (en) * 2015-11-03 2017-05-11 Lu License Ab Compounds for treatment of hypoproliferative disorders

Also Published As

Publication number Publication date
CN113677341A (zh) 2021-11-19
WO2020160537A1 (en) 2020-08-06
AU2020216498A1 (en) 2021-09-23
CA3128377A1 (en) 2020-08-06
CN113677341B (zh) 2024-07-05
US11572369B2 (en) 2023-02-07
EP3917523A4 (en) 2022-10-19
EP3917523C0 (en) 2024-09-11
JP2022523742A (ja) 2022-04-26
US20220135583A1 (en) 2022-05-05
ES2991429T3 (es) 2024-12-03
EP3917523A1 (en) 2021-12-08
EP3917523B1 (en) 2024-09-11
JP7628252B2 (ja) 2025-02-10

Similar Documents

Publication Publication Date Title
KR101920456B1 (ko) 신규한 이미다조피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
EP3235819B1 (en) Pyrrolopyrimidine compounds useful as jak inhibitors
TWI573792B (zh) 新穎治療劑
EP1091942B1 (en) Potassium channel blocking agents
US12479847B2 (en) Pyrrolopyrimidine inhibitors of wild-type and mutant forms of LRRK2
US20210139505A1 (en) PIKfyve Inhibitors
US11014906B2 (en) Quinoline-based compounds and methods of inhibiting CDK8/19
US12521439B2 (en) Methods and materials for modulating Nrf2 pathway
US20220226343A1 (en) 3-amino-4-[4-[4 (dimethylcarbamoyl) phenyl]-1,4-diazepan-1-yl]thieno[2,3-b]pyridine-2-carboxamide for use in cancer therapy and formulations comprising the same
AU2020216498B2 (en) Bicyclic pyridine compositions and methods of using the same for cancer therapy
CN112867493A (zh) 野生型和突变型lrrk2的氮杂吲哚抑制剂
KR101522803B1 (ko) Kat ii 억제제
US6878701B2 (en) Potassium channel blocking agents
US20250312462A1 (en) Pak1 degraders and methods of use thereof
KR20200006495A (ko) N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
CN108472298A (zh) 选择性激酶抑制剂
US12281080B2 (en) Quinoline-based compounds and methods of inhibiting CDK8/19
KR20200088945A (ko) 벤조[b][1,4]옥사제핀 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
KR102328423B1 (ko) 신규 트리아졸로-피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
US20260124310A1 (en) Methods and materials for modulating nrf2 pathway
HK1237763A1 (en) Pyrrolopyrimidine compounds useful as jak inhibitors
HK1237763B (en) Pyrrolopyrimidine compounds useful as jak inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)